SCHEMBL1103564

SCHEMBL1103564

c1ccc2c(-c3ccc(-c4c5ccccc5c(-c5cccc6ccccc56)c5c4cnc4ccccc45)cc3)cccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
GPR3 P46089 1/20 0.40
ENPP1 P22413 2/20 0.39
ENPP3 O14638 1/20 0.39
CA12 O43570 5/20 0.38
CA9 Q16790 5/20 0.38
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
TNF P01375 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
MET P08581 1/20 0.36
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103466 0.96 KDM4E (0.41) KDM4EGPR3ENPP1ENPP3CA12
SCHEMBL1103355 0.96 KDM4E (0.41) KDM4EGPR3ENPP1ENPP3CA12
SCHEMBL1103451 0.93 MAPT (0.42) KDM4EGPR3ENPP1TNFMAPT
SCHEMBL1103558 0.93 MAPT (0.42) KDM4EGPR3ENPP1CA12CA9
SCHEMBL1103393 0.93 TNF (0.43) KDM4EGPR3ENPP1ENPP3CA12
SCHEMBL1103469 0.92 MAPT (0.41) KDM4EGPR3ENPP1CA12CA9
SCHEMBL1103586 0.91 FLT3 (0.41) KDM4EGPR3ENPP1ENPP3MAPT
SCHEMBL1103560 0.90 TNF (0.43) KDM4EGPR3ENPP1ENPP3CA12
SCHEMBL1103487 0.90 MAPT (0.42) KDM4EGPR3TNFMAPTSMN1; SMN2
SCHEMBL1103247 0.90 KDM4E (0.46) KDM4EGPR3CA12CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885GPR3 1503/4885ENPP1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.